x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

15:05

S1 Ep29: Examining Evidence Underlying the NCCN...

Oncology On The Go ·

2021/08/02

This week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues. The conversation focused on the

en-us

14:25

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging...

Oncology On The Go ·

2021/07/30

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL). Visit cancernetwork.com to check out the first episode of this 3-part series here. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple

en-us

15:45

S1 Ep28: Considering Second-Line Treatment Amidst...

Oncology On The Go ·

2021/07/19

This week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD. Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California,

en-us

35:24

S2 Ep6: OncView™ Podcast: Updates in Managing...

Oncology On The Go ·

2021/07/16

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field. In the video series, Levy discussed the following: · Small Cell Lung Cancer: Risk and Prognosis · Small Cell Lung Cancer: Standard of Care · Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment ·

en-us

27:59

S1 Ep27: BPCIA, 4-Letter Suffix Rule, & the...

Oncology On The Go ·

2021/07/05

In this episode, CancerNetwork spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, Executive Director of Oncology Pharmacy Services for RWJBarnabas Health and Director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey. The episode dives into

en-us

26:34

S2 Ep5: Emerging and Existing Treatment Regimens for...

Oncology On The Go ·

2021/06/30

In this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL). Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including

en-us

27:42

S2 Ep4: OncView Podcast: Front-Line Management of...

Oncology On The Go ·

2021/06/28

As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your

en-us

29:42

S1 Ep26: Molecular Profiling Practices in Pancreatic...

Oncology On The Go ·

2021/06/21

This week, "Oncology Peer Review On-The-Go" discussed an article from the May issue of the journal ONCOLOGY titled “Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.” CancerNetwork spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about

en-us

29:07

S2 Ep3: OncView™ Podcast: Management of...

Oncology On The Go ·

2021/06/17

As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options, and considerations for patients with relapsed/refractory follicular lymphoma. In the video series, Gaballa discussed the following: · Treatment Options in Relapsed/Refractory Follicular Lymphoma · Considerations for Treatment Selection in R/R FL · Third-Line Therapy in Follicular Lymphoma · Tazemetostat for

en-us

26:42

S1 Ep25: Primary Focal Therapy for Localized Prostate...

Oncology On The Go ·

2021/06/07

The May issue of the journal ONCOLOGY featured a review article titled “Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature.” Sudhir Isharwal, MD, an assistant professor in the Department of Urology at Oregon Health & Science University in Portland, Oregon, discussed the emergence of focal therapies in the last few years for the treatment of patients with localized prostate cancer. This literature review investigated some of the advantages and drawbacks of various

en-us

14:02

S1 Ep24: Treatment Considerations for...

Oncology On The Go ·

2021/05/24

The feature article for this episode comes from the April issue of the Journal ONCOLOGY titled “Treatment Considerations for Transplant-Ineligible Multiple Myeloma.” Sarah Holstein, MD, an associate professor of internal medicine in the Division of Oncology & Hematology at University of Nebraska Medical Center in Omaha, Nebraska, spoke about the need for further research into treatment options for the older and more frail patient population of multiple myeloma. Holstein also explained the

en-us

16:53

S2 Ep2: OncView Podcast: Optimizing Treatment With...

Oncology On The Go ·

2021/05/19

As part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Extended Adjuvant Therapy for HR+ Breast Cancer · NCCN Updates to Genomic Testing in HR+ Breast Cancer · Genomic Testing for HR+ Breast

en-us

26:18

S2 Ep1: OncView Podcast: Genomic Testing in HR+...

Oncology On The Go ·

2021/05/18

As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer · Predictive and Prognostic Factors in HR+ Breast Cancer ·

en-us

36:20

S1 Ep23: A Critical Interval to Delay Progression of...

Oncology On The Go ·

2021/05/10

This episode features an article published in the April issue of the Journal ONCOLOGY titled “Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.” The lead author of the research, E. David Crawford, MD, a urologic oncologist, and professor of urology at the University of California San Diego, explained their research into prostate cancer disease states. Among other things, Crawford and the research team talked about next-generation imaging, biomarkers, and

en-us

15:21

S1 Ep22: Integrating PARP Inhibitors Into Advanced...

Oncology On The Go ·

2021/04/26

This episode features an article published in the Journal ONCOLOGY titled “Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.” CancerNetwork spoke with the corresponding author, Jun Gong, a medical oncologist at Cedars-Sinai Medical Center, to discuss the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on these PARP inhibitors, Gong also discussed the importance

en-us

16:05

S1 Ep21: 1-on-1 with David Johnson: Enveric's...

Oncology On The Go ·

2021/04/12

In this episode, CancerNetwork sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson gave a thorough background of the biosciences company, and detailed the endocannabinoid products Enveric is developing to positively impact the quality of life for patients with glioblastoma. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast anywhere podcasts are available.

en-us

27:12

S1 Ep20: COVID-19, Cancer, and the Potential of mRNA...

Oncology On The Go ·

2021/03/29

This episode of the "Oncology Peer Review On-The-Go" podcast centers around an article publishing in the April issue of the Journal ONCOLOGY, titled “Messenger RNA Vaccines-Beckoning of a New Era in Cancer Immunotherapy.” The article touches on the recent development of mRNA vaccines approved to combat COVID-19, and how this development offers optimism for the future of mRNA to treat patients with cancer. The author, Mehmet Sitki Copur, MD, of the University of Nebraska Medical Center, broke down

en-us

24:12

S1 Ep19: Impact of Treatment Refusal on Survival for...

Oncology On The Go ·

2021/03/15

In this episode, CancerNetwork examines an article from the March issue of the Journal ONCOLOGY titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of the recommended treatment need to be studied further. CancerNetwork spoke with one of

en-us

17:44

S1 Ep18: 1-on-1 with Richard Schilsky, MD: Molecular...

Oncology On The Go ·

2021/03/01

This week, CancerNetwork sat down for a 1-on-1 conversation with former Chief Medical Officer and Executive Vice President of ASCO, Richard Schilsky, MD, to discuss ASCO’s 2021 "Advance of the Year," molecular profiling driving progress in gastrointestinal cancers. Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving

en-us

31:46

S1 Ep17: Utility of 21-Gene Recurrence Score for...

Oncology On The Go ·

2021/02/15

This week, CancerNetwork examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.” The piece highlights the existing literature regarding the prognostic and predictive capabilities of the 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature. For the summary, CancerNetwork spoke

en-us

236 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter